BR0213897A - uso de uma formulação farmacêutica que compreende um receptor de nucleotìdeo na preparação de medicamento - Google Patents

uso de uma formulação farmacêutica que compreende um receptor de nucleotìdeo na preparação de medicamento

Info

Publication number
BR0213897A
BR0213897A BRPI0213897-2A BR0213897A BR0213897A BR 0213897 A BR0213897 A BR 0213897A BR 0213897 A BR0213897 A BR 0213897A BR 0213897 A BR0213897 A BR 0213897A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
inflammatory
disease
preparation
allergic rhinitis
Prior art date
Application number
BRPI0213897-2A
Other languages
English (en)
Inventor
Ward Peterson
Benjamin R Yerxa
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of BR0213897A publication Critical patent/BR0213897A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UMA FORMULAçãO FARMACêUTICA QUE COMPREENDE UM RECEPTOR DE NUCLEOTìDEO NA PREPARAçãO DE MEDICAMENTO". A presente invenção fornece um método para prevenir ou tratar doença inflamatória, inclusive, sem limitações, sinusite, rinite, conjuntivite, asma, dermatite, doença inflamatória do intestino, doenças vasculares inflamatórias do colágeno, glomerulonefrite, doenças inflamatórias da pele, e sarcoidose. O método compreende administrar a um indivíduo uma formulação farmacêutica que compreende um agonista de receptor de nucleotídeo, tal como um difosfato de nucleosídeo, trifosfato de nucleosídeo, ou polifosfato de dinucleosídeo, de acor com as Fórmulas genéricas Ia, Ib, IIa, IIb ou III. As indicações preferidas da presente invenção são rinite alérgica perene, rinite alérgica sazonal, rinite alérgica infecciosa e conjuntivite alérgica.
BRPI0213897-2A 2001-11-06 2002-11-06 uso de uma formulação farmacêutica que compreende um receptor de nucleotìdeo na preparação de medicamento BR0213897A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33782801P 2001-11-06 2001-11-06
PCT/US2002/035775 WO2003039473A2 (en) 2001-11-06 2002-11-06 Method for treating or preventing inflammatory diseases

Publications (1)

Publication Number Publication Date
BR0213897A true BR0213897A (pt) 2006-05-23

Family

ID=23322192

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0213897-2A BR0213897A (pt) 2001-11-06 2002-11-06 uso de uma formulação farmacêutica que compreende um receptor de nucleotìdeo na preparação de medicamento

Country Status (11)

Country Link
US (1) US7256183B2 (pt)
EP (1) EP1450820A4 (pt)
JP (1) JP2005532254A (pt)
KR (1) KR20050043761A (pt)
CN (1) CN1612739A (pt)
AR (1) AR037263A1 (pt)
BR (1) BR0213897A (pt)
CA (1) CA2465894A1 (pt)
MX (1) MXPA04004215A (pt)
TW (1) TW200300692A (pt)
WO (1) WO2003039473A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
JPWO2004075906A1 (ja) * 2003-02-26 2006-06-01 リジェンティス株式会社 抗炎症剤及び抗炎症性医療材料
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
SE529064C2 (sv) * 2005-01-03 2007-04-24 Selectica Pharmaceuticals Ab Topiska kompositioner
GB0502250D0 (en) * 2005-02-03 2005-03-09 Ic Vec Ltd Use
US20080227689A1 (en) * 2005-09-29 2008-09-18 Jamey Marth Dampening Humoral and Innate Immunity by Inhibition of Ppgalnact-1
WO2008113072A2 (en) * 2007-03-15 2008-09-18 Board Of Regents, The University Of Texas System Gpcr enhanced neuroprotection to treat brain injury
US8168597B2 (en) * 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
US10111904B2 (en) * 2013-01-09 2018-10-30 Berlock Aps Micron-sized gold, kit comprising said gold and its use as a non-toxic immune suppressor
US20150031712A1 (en) * 2013-03-12 2015-01-29 Moshe Rogosnitzky Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same
GB201320959D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US6255059B1 (en) 1993-03-31 2001-07-03 Cadus Pharmaceutical Corporation Methods for identifying G protein coupled receptor effectors
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US6147056A (en) * 1995-06-06 2000-11-14 Trustees Of Boston University Use of locally applied DNA fragments
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6423694B1 (en) 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
JP4271730B2 (ja) 1996-03-27 2009-06-03 インスパイアー ファーマシューティカルズ，インコーポレイティド ウリジン三リン酸及び関連化合物による線毛ジスキネシアの治療方法
US5968913A (en) 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998015835A1 (en) 1996-10-08 1998-04-16 Inspire Pharmaceuticals, Inc. Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances
EP0929218A4 (en) * 1996-10-30 2001-05-16 Univ North Carolina R2Y RECEPTOR ANTAGONISTS
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
ES2264197T3 (es) * 1997-02-06 2006-12-16 Inspire Pharmaceuticals, Inc. Dinucleotidos y sus usos.
JP2001518118A (ja) * 1997-03-25 2001-10-09 アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ ヒト肥満細胞活性化のモジュレーション
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
JP2001513568A (ja) * 1997-08-29 2001-09-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 肺疾患を治療するためのウリジン５’−ジホスフェートとその類似体の使用
AU746750B2 (en) 1998-05-22 2002-05-02 Inspire Pharmaceuticals, Inc. Therapeutic dinucleotide and derivatives
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
AR023088A1 (es) 1999-02-26 2002-09-04 Inspire Pharmaceuticals Inc Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas.
CA2395108A1 (en) * 1999-12-22 2001-06-28 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US6610274B1 (en) * 2000-12-22 2003-08-26 Wallace J. Gardner Anti-inflammatory composition comprising tetracycline
US20040241149A1 (en) * 2001-09-05 2004-12-02 Claudio De Simone Use of unmethylatd cpg

Also Published As

Publication number Publication date
KR20050043761A (ko) 2005-05-11
JP2005532254A (ja) 2005-10-27
US7256183B2 (en) 2007-08-14
TW200300692A (en) 2003-06-16
EP1450820A2 (en) 2004-09-01
WO2003039473A2 (en) 2003-05-15
CA2465894A1 (en) 2003-05-15
AR037263A1 (es) 2004-11-03
MXPA04004215A (es) 2004-07-08
EP1450820A4 (en) 2009-02-18
US20030125299A1 (en) 2003-07-03
WO2003039473A3 (en) 2003-10-23
CN1612739A (zh) 2005-05-04

Similar Documents

Publication Publication Date Title
BRPI0622298A8 (pt) Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
BR0213897A (pt) uso de uma formulação farmacêutica que compreende um receptor de nucleotìdeo na preparação de medicamento
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
MY143795A (en) Tetrahydropyridoindole derivatives
NZ608673A (en) Therapeutic use of a tlr agonist and combination therapy
BR0302965A (pt) Composto e método de tratar doenças mediadas por receptores de adenosina a2b
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
UY30513A1 (es) Composiciones de modificador de respuesta inmune y metodos
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
IL186104A (en) Phosphoramidate History of Nucleoside Compounds
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
BRPI0514736A (pt) inibidores do receptor sigma
UA95715C2 (ru) Фосфадиазиновые производные, фармацевтическая композиция и их применение
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
MX2009013321A (es) Derivados de espiro[piperidin-4,4'-tieno[3,2-c]pirano] y compuestos relacionados como inhibidores del receptor sigma para el tratamiento de psicosis.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
WO2007097989A3 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
MY133995A (en) 6-phenylpyrrolopyrimidinedione derivatives
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
MY145448A (en) Acylated nonadepsipeptides used as lysobactin derivatives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.